ÂÜÀòÂÒÂ×

Mr. Oliviero is the President and CEO of Checkpoint Therapeutics, a member of Checkpoint’s Board of Directors and has more than twenty years of operational experience in the biotechnology industry. Prior to Checkpoint, Mr. Oliviero served in a variety of leadership roles, most recently as Chief Financial Officer at Keryx Biopharmaceuticals, where he played a key role in growing the company to a market capitalization over $1 billion and completed over $500 million in various public financings. During his time at Keryx, Mr. Oliviero was a leading member of the design of several clinical studies and the regulatory oversight of Keryx’s new drug application for Auryxia™, which successfully obtained FDA marketing approval in 2014 and EMA marketing approval in 2015. Prior to Keryx, Mr. Oliviero was Director of Finance for ACCESS Oncology. Mr. Oliviero is a CFA charterholder and holds a B.B.A. in Finance with Highest Distinction from Emory University’s Goizueta Business School.